Your Health, We Care
Release date: 2026-01-23 17:52:16 Recommended: 10
Lorlatinib is a third-generation dual-target inhibitor of ALK/ROS1, primarily indicated for the treatment of ALK-positive advanced non-small cell lung cancer (NSCLC). It is particularly recommended for patients who have developed resistance to first-generation targeted therapies (such as crizotinib and alectinib) or present with brain metastases. Clinical studies have demonstrated that its objective response rate (ORR) ranges from 48% to 57%, with remarkable efficacy in controlling brain metastatic lesions.
Patient Population: Patients with advanced NSCLC harboring ALK or ROS1 gene mutations, especially those who have failed previous treatments or have brain metastases.
Mechanism of Action: Lorlatinib exerts its therapeutic effect by inhibiting the abnormal activation of ALK and ROS1 proteins, thereby blocking the tumor cell proliferation signaling pathway and delaying disease progression.
In clinical studies involving patients resistant to prior ALK inhibitors, the median progression-free survival (PFS) with lorlatinib was 6.2 to 11.1 months, significantly prolonging the duration of disease control.
Owing to its high blood-brain barrier penetration, lorlatinib achieves an intracranial objective response rate (ORR) of over 60% for brain metastatic lesions, leading to tumor shrinkage or complete resolution in some patients.
Preliminary data from certain studies suggest that the 3-year progression-free survival rate with first-line lorlatinib therapy can reach 64%, though this finding requires validation with larger-scale clinical trials.
Hypercholesterolemia (72%), edema (43%), and peripheral neuropathy (34%) are among the most frequent side effects. The majority of these reactions are mild to moderate (Grade 1-2) and manageable.
Severe adverse events include central nervous system (CNS) effects (e.g., cognitive impairment, mood swings) and interstitial lung disease (ILD), which is rare but requires prompt medical attention.
Regular monitoring of blood lipid levels, liver function, and neurological symptoms is mandatory. Dose adjustment or temporary treatment suspension is required in case of severe adverse reactions.
Lorlatinib is a prescription-only medication. Treatment regimens must be individualized by physicians based on genetic testing results, prior treatment history, and the patient’s overall health status.
If disease progression occurs during treatment, re-evaluation of genetic mutations is necessary. Combination therapy with chemotherapy or immunotherapy may be considered when appropriate.
Imaging examinations and tumor marker tests should be conducted every 2–3 months during treatment. For patients with brain metastases, additional follow-up with brain magnetic resonance imaging (MRI) is recommended.
In summary, lorlatinib represents a crucial second-line or later treatment option for ALK-positive NSCLC patients, with outstanding performance in controlling brain metastases and overcoming drug resistance. However, strict management of adverse reactions and adherence to the principle of personalized treatment are essential for optimal therapeutic outcomes.
